183 related articles for article (PubMed ID: 8259546)
1. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
[TBL] [Abstract][Full Text] [Related]
2. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
3. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
Bendayan P; Boccalon H; Dupouy D; Boneu B
Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383
[TBL] [Abstract][Full Text] [Related]
4. Highly sulfated dermatan sulfate from the skin of the ray Raja montagui: anticoagulant activity and mechanism of action.
Ben Mansour M; Dhahri M; Hassine M; Ajzenberg N; Venisse L; Ollivier V; Chaubet F; Jandrot-Perrus M; Maaroufi RM
Comp Biochem Physiol B Biochem Mol Biol; 2010 Jul; 156(3):206-15. PubMed ID: 20363356
[TBL] [Abstract][Full Text] [Related]
5. Effect of oversulfated dermatan sulfate derivatives on platelet aggregation.
Maaroufi RM; Giordano P; Triadou P; Tapon-Bretaudière J; Dautzenberg MD; Fischer AM
Thromb Res; 2007; 120(4):615-21. PubMed ID: 17222891
[TBL] [Abstract][Full Text] [Related]
6. Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans.
Cosmi B; Cini M; Legnani C; Pancani C; Calanni F; Coccheri S
Thromb Res; 2003 Mar; 109(5-6):333-9. PubMed ID: 12818259
[TBL] [Abstract][Full Text] [Related]
7. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of thrombin inhibition by heparin cofactor II and antithrombin in the presence of the ray (Raja radula) skin dermatan sulfate.
Ben Mansour M; Dhahri M; Vénisse L; Jandrot-Perrus M; Chaubet F; Maaroufi RM
Thromb Res; 2009 Apr; 123(6):902-8. PubMed ID: 19046760
[TBL] [Abstract][Full Text] [Related]
9. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
10. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.
Chan AK; Berry LR; Monagle PT; Andrew M
Thromb Haemost; 2002 Apr; 87(4):606-13. PubMed ID: 12008942
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
13. The relationship between the structure of dermatan sulfate derivatives and their antithrombotic activities.
Du HY; Ji SL; Song HF; Ye QN; Cao JC
Thromb Res; 2007; 119(3):377-84. PubMed ID: 17097136
[TBL] [Abstract][Full Text] [Related]
14. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel dermatan sulfate with high antithrombin activity from ray skin (Raja radula).
Ben Mansour M; Dhahri M; Bertholon I; Ollivier V; Bataille I; Ajzenberg N; Hassine M; Jandrot-Perrus M; Chaubet F; Maaroufi RM
Thromb Res; 2009 Apr; 123(6):887-94. PubMed ID: 19019412
[TBL] [Abstract][Full Text] [Related]
17. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
Cimenti C; Koestenberger M; Leschnik B; Haidl H; Muntean W
Thromb Res; 2007; 119(3):361-7. PubMed ID: 16712904
[TBL] [Abstract][Full Text] [Related]
18. Insight into the profibrinolytic activity of dermatan sulfate: effects on the activation of plasminogen mediated by tissue and urinary plasminogen activators.
Castañon MM; Gamba C; Kordich LC
Thromb Res; 2007; 120(5):745-52. PubMed ID: 17270255
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin.
Gerotziafas GT; Dupont C; Spyropoulos AC; Hatmi M; Samama MM; Kiskinis D; Elalamy I
Thromb Haemost; 2009 Jul; 102(1):42-8. PubMed ID: 19572066
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
